Display Settings:

Format

Send to:

Choose Destination
    Mol Cell. 2011 Oct 21;44(2):170-1.

    Mitochondrial SIRT3: a new potential therapeutic target for metabolic syndrome.

    Source

    Department of Developmental Biology, Washington University School of Medicine, St. Louis, MO 63110, USA.

    Abstract

    In this issue of Molecular Cell, Hirschey et al. demonstrate that loss of the NAD(+)-dependent deacetylase SIRT3 and resultant mitochondrial protein hyperacetylation play a critical role in the pathogenesis of metabolic syndrome, providing new insights into the therapeutic potential of SIRT3.

    Copyright © 2011 Elsevier Inc. All rights reserved.

    PMID:
    22017865
    [PubMed]
    PMCID:
    PMC3215590
    [Available on 2012/10/21]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk